` 4536 (Santen Pharmaceutical Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4536
vs
Nikkei 225

Over the past 12 months, has outperformed Nikkei 225, delivering a return of 2% compared to the Nikkei 225's 10% drop.

Stocks Performance
4536 vs Nikkei 225

Loading

Performance Gap
4536 vs Nikkei 225

Loading
4536
Nikkei 225
Difference

Performance By Year
4536 vs Nikkei 225

Loading
4536
Nikkei 225
Add Stock

Competitors Performance
Santen Pharmaceutical Co Ltd vs Peers

Nikkei 225
4536
LLY
JNJ
NOVO B
ROG
Add Stock

Santen Pharmaceutical Co Ltd
Glance View

Economic Moat
None
Market Cap
496.3B JPY
Industry
Pharmaceuticals

Santen Pharmaceutical Co., Ltd., a cornerstone of Japan's robust pharmaceutical industry, has been relentlessly focused on improving eye health worldwide. Founded in 1890, the company began as a modest medicine retailer in Osaka, but over the decades, it has skillfully navigated the evolving healthcare landscape to become a global leader in ophthalmology. Today, Santen's enterprise is intricately woven with innovation and specialization, stretching its influence far beyond its Japanese roots. Its main thrust lies in the research, development, and commercialization of ophthalmic products tackling a comprehensive range of eye disorders, from dry eyes to age-related macular degeneration and glaucoma. By investing significantly in R&D, Santen maintains a robust pipeline of new treatments that continuously feeds into its growing portfolio, ensuring its offerings are at the forefront of medical advancements. Santen's business strategy thrives on leveraging its scientific expertise to not only create but also efficiently bring products to market across various continents. It operates through a well-crafted distribution network that spans Asia, Europe, and North America, tailoring its marketing and regulatory approaches to suit regional healthcare environments. This global footprint allows Santen to capture diverse markets, each with unique demands, thereby enhancing revenue streams. The firm's operational model also includes strategic partnerships and acquisitions, enhancing its research capabilities and expanding its market share to sustain profitability. Santen generates revenue primarily through the sale of innovative ophthalmic prescription drugs and over-the-counter products, supported by its strong relationships with healthcare professionals and continued expansion into emerging markets. The company’s focused strategy and commitment to eye health solutions position it as an indispensable player in the global healthcare industry.

Intrinsic Value
2 108.42 JPY
Undervaluation 31%
Intrinsic Value
Price
Back to Top